newsfilter
← Latest News
Business Wire·

Human Genome Sciences Board of Directors to Review Unsolicited Tender Offer From GlaxoSmithKline

ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today confirmed that GlaxoSmithKline plc (GSK) has announced its intention to commence an unsolicited tender offer to acquire all the outstanding common shares of HGS at a price of $13.00 per share in cash.